​

BriaCell Therapeutics Stock (NASDAQ:BCTX)

OwnershipFinancialsChart
BriaCell Therapeutics by TradingView

Previous Close

$3.63

52W Range

$2.98 - $36.90

50D Avg

$4.05

200D Avg

$7.06

Market Cap

$6.74M

Avg Vol (3M)

$220.24K

Beta

1.63

Div Yield

-

BCTX Company Profile

BriaCell Therapeutics Corp., an immuno-oncology biotechnology company, engages in developing immunotherapies for the treatment of cancer. Its lead candidate is Bria-IMT that is in Phase I/IIa clinical trial in a combination study with immune checkpoint inhibitors for the treatment of breast cancer. The company also has a cooperative research and development agreement with the National Cancer Institute for developing Bria-OTS, a personalized immunotherapy for advanced breast cancer; and BriaDx, a diagnostic test. BriaCell Therapeutics Corp. is headquartered in West Vancouver, Canada.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

CA

Employees

16

IPO Date

Mar 14, 2012

Website

BCTX Performance

BCTX Financial Summary

Jul 25Jul 24Jul 23
Revenue---
Operating Income-$-46.02K$-23.27M
Net Income$-26.31M$-6.62K$-20.30M
EBITDA-$-45.91K$-22.37M
Basic EPS-$-4.28$-19.79
Diluted EPS-$-4.28$-19.79

Fiscal year ends in Jul 25 | Currency in USD

Peer Comparison

TickerCompany
ASBPAspire Biopharma Holdings, Inc.
HOTHHoth Therapeutics, Inc.
MBRXMoleculin Biotech, Inc.
PCSAProcessa Pharmaceuticals, Inc.
CRISCuris, Inc.
LPTXLeap Therapeutics, Inc.
ALLRAllarity Therapeutics, Inc.
CTXRCitius Pharmaceuticals, Inc.
PALIPalisade Bio, Inc.